Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
Verona Pharma plc (Nasdaq: VRNA) announced it will report its financial results for Q1 2022 on May 3, 2022, followed by a conference call at 9:00 a.m. EDT. The company focuses on treatments for respiratory diseases, with its key product candidate ensifentrine undergoing Phase 3 clinical trials for COPD. Ensifentrine may offer unique bronchodilator and anti-inflammatory effects. The call can be accessed via telephone or a live webcast available on the company's website. For more details, visit www.veronapharma.com.
- Ensifentrine is being evaluated in a Phase 3 clinical program for COPD maintenance treatment.
- The product candidate may combine bronchodilator and anti-inflammatory effects, addressing an unmet medical need.
- None.
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three months ended March 31, 2022 on Tuesday, May 3, 2022 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
To participate, please dial one of the following numbers and reference conference ID 2045514:
- +1-888-317-6003 for callers in the United States
- +1-412-317-6061 for international callers
A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.
For further information please contact:
| Verona Pharma plc | US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200 |
| Victoria Stewart, Director of Investor Relations and Communications | info@veronapharma.com |
| Argot Partners (US Investor Enquiries) | Tel: +1-212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Michael Barron | |
| Optimum Strategic Communications (International Media and European Investor Enquiries) | Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
| Mary Clark / Rebecca Noonan / Zoe Bolt |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
When will Verona Pharma report its financial results for Q1 2022?
What is the focus of Verona Pharma?
What is ensifentrine and its significance?
How can I access the conference call on May 3, 2022?
